secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001213900-24-050365
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Nektar shareholders elect three directors, approve 8M share increase, ratify auditor
--------------------------------------------------------------------------------

- Elected directors Jeff Ajer, Robert B. Chess, Roy A. Whitfield with broker non-votes of 46.7M each.
- Approved amendment to 2017 Performance Incentive Plan adding 8M shares; 86.5M for, 7.5M against.
- Ratified Ernst & Young as independent auditor for FY2024: 139M for, 1.6M against, 6M abstain.
- Non-binding say-on-pay approved: 87M for, 6.7M against, 6.2M abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390024050365/0001213900-24-050365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390024050365/ea0207441-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-050365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer